{"id":447587,"date":"2021-03-01T16:33:25","date_gmt":"2021-03-01T21:33:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=447587"},"modified":"2021-03-01T16:33:25","modified_gmt":"2021-03-01T21:33:25","slug":"lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/","title":{"rendered":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>LEXEO completes license of all intellectual property rights and pre-clinical data associated with<\/em><br \/>\n        <em>Adverum<\/em><br \/>\n        <em>Biotechnologies\u2019 investigational Friedreich\u2019s<\/em><br \/>\n        <em>ataxia program<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Pre-clinical research licensed from academic partners and data from Adverum\u2019s program now<\/em><br \/>\n        <em>consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in<\/em><br \/>\n        <em>2021<\/em>\n      <\/p>\n<p>NEW YORK, March  01, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LZdlFfUKaCp4P2CEl575L6oy1UO7aYIQXSWWy3dSMbvtef9Ykq08KzsfUwWS6Of3hWegKKYsK7olozxpDO68nw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LEXEO Therapeutics<\/a>, a clinical-stage gene therapy company, today announced it has\u00a0licensed worldwide intellectual property rights and pre-clinical data from Adverum Biotechnologies to its Friedreich&#8217;s ataxia gene therapy program. With exclusive rights to data from seven pre-clinical studies now combined, LEXEO will advance LX2006 through final IND-enabling studies and into a planned Phase 1 clinical trial in 2021.<\/p>\n<p>LX2006 is an adeno-associated virus (AAV)-mediated treatment delivered through intravenous administration to address the Friedreich&#8217;s ataxia cardiac disease pathology, the most common cause of mortality in people with Friedreich&#8217;s ataxia. This program is supported by seven distinct pre-clinical studies conducted at preeminent scientific institutions in France and the United States examining multiple vector constructs, dose ranges and routes of administration, all contributing to the optimization of the current LX2006 program construct that will be taken forward into the clinic this year. In several pre-clinical studies, LX2006 has <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DERSOxqP_z7l0C0oGcBZRtwv_VOqXAgZBo18XNLAuLuFRPEDnYghe9AETTUhIwHaro8kO7sA7rqXE6C36KGRYEp-qBfkYjqhUcGYi1DsHIdi2q8cLzOAVX0eDOFHxgzQ\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>demonstrated<\/u><u>efficacy<\/u><\/a> in reversing the abnormal cardiac phenotype in Friedreich&#8217;s ataxia disease models by transferring a normal frataxin gene to the heart.<\/p>\n<p>\u201cOur agreement with Adverum, adding to studies conducted by other academic partners, greatly strengthens our pre-clinical data package supporting LX2006, our gene therapy program addressing cardiomyopathy associated with Friedreich\u2019s ataxia,\u201d said R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics. \u201cCardiomyopathy is the cause of mortality in up to 70% of Friedreich&#8217;s ataxia patients. Our goal is to address this challenging component of Friedreich&#8217;s ataxia with the first potentially disease-modifying therapy for this underserved patient population.\u201d<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>Friedreich\u2019s<\/strong><br \/>\n        <strong>Ataxia<\/strong><br \/>\n        <br \/>Friedreich\u2019s ataxia (FA) is a rare, degenerative multi-system disorder affecting approximately 1 in 50,000 people in the United States. FA is caused by a gene mutation that disrupts the normal production of the protein frataxin, critical to the function of mitochondria (the energy producing factories) in a cell. FA is inherited in an autosomal recessive manner, usually begins in childhood, and leads to impaired muscle coordination (ataxia) that worsens over time, typically progressing to serious heart conditions, including hypertrophic cardiomyopathy and arrythmias. FA is also associated with vision impairment, hearing loss, scoliosis, diabetes and slurred speech. Friedreich\u2019s ataxia can shorten life expectancy, and heart failure is the most common cause of death. LX2006 is an IV-administered, AAV-mediated frataxin gene therapy treatment focused on the cardiac pathology of FA.\u00a0LEXEO Therapeutics is completing IND-enabling pre-clinical studies and expects to initiate a Phase 1 trial in 2021.<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>LEXEO<\/strong><br \/>\n        <strong>Therapeutics,<\/strong><br \/>\n        <strong>Inc.<\/strong><br \/>\n        <br \/>LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center\u00ae for Life Science that aims to apply the transformational science of gene therapy to address some of the world\u2019s most devastating genetic and acquired diseases. LEXEO Therapeutics\u2019 pipeline consists of adeno-associated virus (AAV)- mediated therapies primarily developed at Weill Cornell Medicine\u2019s Department of Genetic Medicine. Beyond LEXEO Therapeutics\u2019 lead programs \u2013 which are focused on both rare and non-rare monogenic (single gene mutation) diseases \u2013 the company\u2019s pre-clinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine\u2019s Department of Genetic Medicine to help advance the company\u2019s pre-clinical pipeline. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FroIy3GSY_soZO3i5DleBajjzvsMdN8qNO3WVZik1dpaj7VzSfuqm2Cxr_1cGaP-dtpECnqLW3slN_XbmCKSnA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.lexeotx.com<\/u><\/a>or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fg-7nea-2P4gnDyq_IOE4XuLOm5R0sdxjqk9AIVQDXsl84eZb4EhZHkhI1AxGse5ijk2g0KgHz_-Dx4rmKQgJ7iK75QIEiEMRo9dUdriu0FvshvEe3L5Kb42n2mcBaOH\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor<\/strong><br \/>\n        <strong>Contact<br \/><\/strong>LEXEO Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SXR__lo3Opx2Osw2DyVi1NVhdNriXQZjCs5YK7rjCNp_wvMU5wfppD77SDq91H9PlofVsvfH5_69YyYILV4TbbGaiRLVpGFVNv7AHw5-BMU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>investors@lexeotx.com<\/u><\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <strong>Contact<\/strong><br \/>\n        <br \/>Sheryl Seapy, W2O Group (949) 903-4750<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bQkXXABK1u2Tqyun5SK8pJudtP2fvyFnjshnMSq-yY4X6O35r_KzvGQBTgaM_3VRx_WPOXaIXOZK_YVFb3DaiQpWA04lDFZmP472j41rzkA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sseapy@w2ogroup.com<\/a><\/u><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/976c4869-83f4-4642-8249-f4fa76b7da2d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies\u2019 investigational Friedreich\u2019s ataxia program Pre-clinical research licensed from academic partners and data from Adverum\u2019s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) &#8212; LEXEO Therapeutics, a clinical-stage gene therapy company, today announced it has\u00a0licensed worldwide intellectual property rights and pre-clinical data from Adverum Biotechnologies to its Friedreich&#8217;s ataxia gene therapy program. With exclusive rights to data from seven pre-clinical studies now combined, LEXEO will advance LX2006 through final IND-enabling studies and into a planned Phase 1 clinical trial in 2021. LX2006 is an adeno-associated virus (AAV)-mediated treatment delivered &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-447587","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#039;s Ataxia Gene Therapy Program (LX2006) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#039;s Ataxia Gene Therapy Program (LX2006) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies\u2019 investigational Friedreich\u2019s ataxia program Pre-clinical research licensed from academic partners and data from Adverum\u2019s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) &#8212; LEXEO Therapeutics, a clinical-stage gene therapy company, today announced it has\u00a0licensed worldwide intellectual property rights and pre-clinical data from Adverum Biotechnologies to its Friedreich&#8217;s ataxia gene therapy program. With exclusive rights to data from seven pre-clinical studies now combined, LEXEO will advance LX2006 through final IND-enabling studies and into a planned Phase 1 clinical trial in 2021. LX2006 is an adeno-associated virus (AAV)-mediated treatment delivered &hellip; Continue reading &quot;LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T21:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)\",\"datePublished\":\"2021-03-01T21:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/\"},\"wordCount\":647,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/\",\"name\":\"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\",\"datePublished\":\"2021-03-01T21:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/","og_locale":"en_US","og_type":"article","og_title":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) - Market Newsdesk","og_description":"LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies\u2019 investigational Friedreich\u2019s ataxia program Pre-clinical research licensed from academic partners and data from Adverum\u2019s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) &#8212; LEXEO Therapeutics, a clinical-stage gene therapy company, today announced it has\u00a0licensed worldwide intellectual property rights and pre-clinical data from Adverum Biotechnologies to its Friedreich&#8217;s ataxia gene therapy program. With exclusive rights to data from seven pre-clinical studies now combined, LEXEO will advance LX2006 through final IND-enabling studies and into a planned Phase 1 clinical trial in 2021. LX2006 is an adeno-associated virus (AAV)-mediated treatment delivered &hellip; Continue reading \"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-01T21:33:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)","datePublished":"2021-03-01T21:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/"},"wordCount":647,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/","name":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==","datePublished":"2021-03-01T21:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MTg1MyMzOTk4NzcxIzUwMDA3Njc1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-announces-license-agreement-and-consolidation-of-comprehensive-pre-clinical-data-package-to-support-cardiac-friedreichs-ataxia-gene-therapy-program-lx2006\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich&#8217;s Ataxia Gene Therapy Program (LX2006)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=447587"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/447587\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=447587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=447587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=447587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}